Prof. Pietro Lampertico
Login if you had registered for the Combined GIHep and Singapore Hepatology Conference 2024.
The Science Of
HBV Cure
Meeting 2024
The Science Of Hbv Cure Meeting 2024
To View SHC 2024 Videos and Download PDF Slides:
To view the menu of slides and video recordings from any year, please click on the e-Resources tab.
If you wish to watch videos and download slides of past conferences up to SHC 2022, you must register or log in to the Website. Videos and Slides up to SHC 2022 are available free of charge..
If you had registered as a premium user in 2023, you will continue to have access to 2023 materials.
Some of the Experts You can Watch on Video
Prof. Pietro Lampertico
Prof. MF Yuen
Prof. Antonio Bertoletti
Prof. Lim Seng Gee
The Science of HBV Cure Meeting 2024 Scientific Programme.
July, 2024
26
| Programme | Time (SGT) |
|---|---|
| Welcome Remarks by the Conference Chairman | |
| Opening Symposium: Overview of HBV Functional Cure Moderators: Prof. Pietro Lampertico, Prof. Seng Gee Lim |
|
| HBV Cure: definitions and prospects – Prof. Pietro Lampertico, Italy |
|
| The Role of ICE-HBV in HBV functional cure – Prof. Massimo Levrero, France |
|
| Are HBV flares necessary for functional cure? – Prof. Kumar Visvanathan, Australia |
|
| Virological Insights into functional cure Moderators: Prof. Thomas Tu, Dr. Jayantha Gunaratne |
|
| Is cccDNA silenced or lost in functional cure? – Prof. Massimo Levrero, France |
|
| Removing integrated HBV – Prof. Thomas Tu, Australia |
|
| New virological targets leading to functional cure – Prof. Pei Jer Chen, Taiwan |
|
| Free Paper: The role of HBx in functional cure – Dr. Aravind Sivakumar, Singapore |
|
| Free paper: BMP pathway is a target for functional cure – Dr. Jayantha Gunaratne |
|
| Free paper: HBV functional cure is related to baseline qHBsAg and interferon response – Prof. Seng Gee Lim, Singapore |
|
| Lunch | |
| Immunological insights into functional cure Moderator: Dr. Valerie Chew |
|
| What we have learnt from interrogating the liver microenvironment : A review – Dr. Ram DasGupta, Singapore |
|
| Understanding the immune mechanisms to achieve functional cure – Prof. Eui-Cheol Shin, Korea |
|
| Free Paper Presentations | |
| Free paper: The Role of STING Signaling Pathway in Chronic Hepatitis B: Implications for Immune Status – Dr. Zhang Mingyuan |
|
| Animal Models Moderator: Prof. Eui-Cheol Shin, Prof. Massimo Levrero |
|
| A humanized animal model with matching immune system – Dr. Qingfeng Chen, Singapore |
|
| Animal model forum: How to use animal models in HBV drug development – Prof. Pei-Jer Chen, Dr. Qingfeng Chen, Dr. Guofeng Cheng, Dr. Zhi Hong |
|
| Capsid Assemby Modulators Moderator: Prof. Harry Janssen |
|
| The role of Capsid Assembly Modulators in functional cure – Prof. Man Fung Yuen, Hong Kong |
|
| Invited Pharma Presentations Moderator: Prof. Harry Janssen |
|
| Preclinical Profiling of ABI-6250, a Novel Orally Bioavailable Small-Molecule Therapeutic Candidate for the Treatment of Chronic Hepatitis (Virtual) – Dr. Marc Windisch, Assembly Biosciences |
|
| Aligos Assets for HBV functional cure – Dr. Min Wu, Aligos Therapeutics |
|
| Tea Break | |
| Biomarkers Moderator: Prof. Seng Gee Lim |
|
| Biomarkers for functional cure – Prof. Man-Fung Yuen, Hong Kong |
|
| Free paper: progress in biomarker discovery for HBV functional cure – Dr. Zijie Lim, Singapore |
|
| Invited Pharma Presentations | |
| The performance and clinical utility of novel highly sensitive iTACT-HBsAg and iTACT-HBcrAg assays – Dr. Kazuyoshi Miyamoto, Fujirebio |
|
| Your partner in HBV management (Virtual) – Dr. Mark Anderson, Abbott Diagnostics |
|
| Closing remarks | |
| End of day 1 | |
July, 2024
27
| Programme | Time (SGT) |
|---|---|
| Special Lecture Moderators: Prof.Thomas Tu, Prof. Massimo Levrero |
|
| Gene Editing for complete cure: state of the art – Dr. Kosh Agarwal, United Kingdom |
|
| RNA interference Moderators: Prof. Thomas Tu, Prof. Massimo Levrero |
|
| Anti-sense vs siRNA: can we explain the efficacy differences? – Prof. Pei-Jer Chen, Taiwan |
|
| Invited Pharma Presentations Moderators: Prof. Thomas Tu, Prof. Massimo Levrero |
|
| Roche strategy for functional cure – Dr. Farouk Chughlay, Roche |
|
| Bepirovirsen immune mechanism of action may potentiate infected hepatocyte killing: Indirect evidence from B-together peripheral longitudinal biomarker analysis – Dr. Shilpy Joshi, GSK |
|
| AHB-137, a novel ASO for HBV Cure – Dr. Guofeng Cheng, Ausperbio Therapeutics Inc |
|
| Update on Nucleic Acid Polymers (Virtual) – Dr. Andrew Vaillant, Replicor |
|
| Tea Break | |
| Delta Cure Moderator: Prof. Lim Seng Gee |
|
| Path to Delta Cure – Prof. Heiner Wedemeyer, Germany |
|
| The role of NAPs in Delta Therapy (Virtual) – Dr. Andrew Valliant, Replicor |
|
| Immunology Chair and moderator: Dr. Valerie Chew |
|
| Insights into HBV Cure from studies of novel immune modulators (Virtual) – Prof. Antonio Bertoletti, Singapore |
|
| Free paper: The differentiation of Treg and Th17 cells in patients with chronic hepatitis B in different stages – Dr. Le Thi Thuy Hang, Vietnam |
|
| Lunch | |
| Invited pharma Presentations Moderators: Prof. Kumar Visvanathan |
|
| Characterisation of Selgantolimod (TLR8 agonist) against CHB (Virtual) – Dr. Frida Abramov, Gilead Sciences |
|
| Clonal amplification of peripheral CD8+ T cells is associated with clinical response to checkpoint blockade in chronic hepatitis B (Virtual) – Dr. Jeff Wallin, Gilead Sciences |
|
| Insights into CHB functional cure from Ascletis studies (Virtual) – Dr. Jinzi J. Wu, Founder, Chairman and CEO, Ascletis |
|
| Achieving breakthroughs in HBV Cure – Dr. Zhi Hong, Brii Bio |
|
| siRNA+Neutralizing antibody combination for HBV Cure – Dr. Wang Dong, Hepa Thera |
|
| The potential role for a novel class, a Checkpoint Modifier, in the functional cure of CHB: the science and clinical data from VRON-0200 (Virtual) – Dr. Sue Currie, Dr. Andrew Luber, Virion Therapeutics |
|
| Tea Break | |
| Treatment strategies Moderators: Prof. Heiner Wedemeyer |
|
| Potential of immune based therapies for functional cure: success and limitations – Prof. Tatsuya Kanto, Japan |
|
| The return of interferon in functional cure strategies – a step backwards? – Prof. Harry Janssen, Holland |
|
| Combination Therapy Forum Moderators: Prof. Seng Gee Lim, Prof. Heiner Wedemeyer |
|
| Immunotherapy and antiviral therapy forum – Prof. Eui Choel Shin, Prof. Massimo Levrero, Prof. Thomas Tu, Prof. Harry Janssen, Prof. Pei-Jer Chen, Prof. Kumar Visvanathan, Dr. Zhi Hong, Dr. Melanie Paff, Dr. Guofeng Cheng |
|
| Closing remarks from Chairman | |